Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T15:25:52.939Z.
Calculation as of: 2026-10-06T15:25:52.939Z.
Quote observation: 2026-10-06T15:25:34.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f9f7ef7d03019e78f4201474ef0c74f9c2a497de6c29d743f28e52983e243880
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2024-04-10.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
EV/EBITDA RATIO AVG TTM
N/A
EV/EBITDA RATIO AVG 3Y
N/A
EV/EBITDA RATIO AVG 5Y
N/A
EV/EBITDA RATIO AVG 10Y
N/A
EV/EBITDA RATIO AVG 15Y
N/A
EV/EBITDA RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Amylyx Pharmaceuticals, Inc.
Market Cap
$3.10B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.09B
EV/EBITDA Ratio
85.27x
TTM Avg
355.62x
3Y Avg
355.62x
5Y Avg
355.62x
Market Cap
$3.12B
EV/EBITDA Ratio
N/A
TTM Avg
116.71x
3Y Avg
116.71x
5Y Avg
116.71x
Market Cap
$2.81B
EV/EBITDA Ratio
27.16x
TTM Avg
35.89x
3Y Avg
85.56x
5Y Avg
85.56x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. (AMLX) | $3.10B | N/A | N/A | N/A | N/A |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.09B | 85.27x | 355.62x | 355.62x | 355.62x |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.09B | N/A | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.12B | N/A | 116.71x | 116.71x | 116.71x |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.89B | N/A | N/A | N/A | N/A |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.39B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.81B | 27.16x | 35.89x | 85.56x | 85.56x |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.41B | N/A | N/A | N/A | N/A |
| CareDx, Inc (CDNA)vs › | $3.41B | 196.55x | 115.31x | 72.49x | 72.49x |
| AtriCure, Inc. (ATRC)vs › | $2.78B | 77.19x | 85.01x | 85.01x | 85.01x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBITDA RATIO |
|---|---|
| 2024-04-10 | 0.11x |
| 2024-04-09 | 0.47x |
| 2024-04-08 | 0.51x |
| 2024-04-05 | 0.38x |
| 2024-04-04 | 0.37x |
| 2024-04-03 | 0.40x |
| 2024-04-02 | 0.38x |
| 2024-04-01 | 0.54x |
| 2024-03-28 | 0.77x |
| 2024-03-27 | 0.84x |
| 2024-03-26 | 0.59x |
| 2024-03-25 | 0.54x |
| 2024-03-22 | 0.59x |
| 2024-03-21 | 0.82x |
| 2024-03-20 | 0.99x |
| 2024-03-19 | 0.92x |
| 2024-03-18 | 0.80x |
| 2024-03-15 | 1.46x |
| 2024-03-14 | 1.34x |
| 2024-03-13 | 1.81x |
| 2024-03-12 | 1.81x |
| 2024-03-11 | 2.43x |
| 2024-03-08 | 1.67x |
| 2024-03-07 | 28.75x |
| 2024-03-06 | 28.89x |
| 2024-03-05 | 28.54x |
| 2024-03-04 | 29.04x |
| 2024-03-01 | 28.30x |
| 2024-02-29 | 28.54x |
| 2024-02-28 | 29.79x |
| 2024-02-27 | 28.80x |
| 2024-02-26 | 26.30x |
| 2024-02-23 | 26.46x |
